Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337643 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
A Phase 1 study of Pneumococcal Vaccine, sponsored by Matrivax Research and Development Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 2
- Study locations
NCT06337643 is a Phase 1 study of Pneumococcal Vaccine that is active but no longer recruiting, run by Matrivax Research and Development Corporation. The registered enrollment target is 75 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06337643, a Phase 1 study of Pneumococcal Vaccine, is active but no longer recruiting, sponsored by Matrivax Research and Development Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
Conditions Studied
Interventions
- BIOLOGICAL MVX01
- BIOLOGICAL MVX01 Placebo
Study Locations (2)
Georgia
- Velocity (Meridian) Clinical Research - Savannah
Tennessee
- Alliance for Multispecialty Research (AMR) - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2023-03-07 |
| Est. Completion | 2024-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06337643
The ClinicalTrials.gov registry entry for NCT06337643 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matrivax Research and Development Corporation, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pneumococcal Vaccine appearing as the primary indexed condition, and to 2 interventions - of which MVX01 is the first listed.
NCT06337643 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06337643 about?
NCT06337643 is a clinical study titled "A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine". The objectives of this first-in-human study is to evaluate the tolerability, safety, and immunogenicity of MVX01, a pneumococcal vaccine candidate, at four dose levels.
What is the current status of trial NCT06337643?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2023-03-07. Estimated completion is 2024-04-16.
What conditions does trial NCT06337643 study?
This clinical trial studies the following conditions: Pneumococcal Vaccine.
What interventions are being tested in trial NCT06337643?
The interventions under investigation include: MVX01 (BIOLOGICAL), MVX01 Placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT06337643?
This trial is sponsored by Matrivax Research and Development Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337643 being conducted?
This trial has 2 study locations across Georgia, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pneumococcal Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.